Javascript must be enabled to continue!
The human complement factor B-C3b complex: Investigation of the interaction using C3b bound to thiol-Sepharose
View through CrossRef
Abstract
Factor B, a serine protease proenzyme and part of the complement system, binds to other complement proteins such as C3b and properdin. While it is known to be activated by factor D, other interactions that interfere with the binding between Factor B and C3b are less well-understood. We attached C3b to a thiol Sepharose via its free SH group and conducted a competition assay employing
125
I-labelled factor B to study competitive binding. Two anti-C3d monoclonal antibodies (F49b and 4C2) were found to partially inhibit the binding of Factor B to C3b. The inhibitory effects of these monoclonal antibodies were found to be dose-dependent. 4C2 was found to have a maximum inhibition of 50%, while the maximum inhibition by F49b was ∼40%. In contrast, two anti-C3c monoclonal antibodies (F39b and F20b) were able to enhance the formation of the factor B-C3b complex in a dose-dependent manner. Competition binding studies with isolated C3 fragments further supported the involvement of the C3d region in factor B binding, as C3d inhibited the binding of factor B to C3b completely. Furthermore, additional competition binding studies conducted with each of the three domains of factor B (Ba, vWF and SP) demonstrated that each domain independently inhibited the binding of intact factor B to C3b by ∼50%.
Title: The human complement factor B-C3b complex: Investigation of the interaction using C3b bound to thiol-Sepharose
Description:
Abstract
Factor B, a serine protease proenzyme and part of the complement system, binds to other complement proteins such as C3b and properdin.
While it is known to be activated by factor D, other interactions that interfere with the binding between Factor B and C3b are less well-understood.
We attached C3b to a thiol Sepharose via its free SH group and conducted a competition assay employing
125
I-labelled factor B to study competitive binding.
Two anti-C3d monoclonal antibodies (F49b and 4C2) were found to partially inhibit the binding of Factor B to C3b.
The inhibitory effects of these monoclonal antibodies were found to be dose-dependent.
4C2 was found to have a maximum inhibition of 50%, while the maximum inhibition by F49b was ∼40%.
In contrast, two anti-C3c monoclonal antibodies (F39b and F20b) were able to enhance the formation of the factor B-C3b complex in a dose-dependent manner.
Competition binding studies with isolated C3 fragments further supported the involvement of the C3d region in factor B binding, as C3d inhibited the binding of factor B to C3b completely.
Furthermore, additional competition binding studies conducted with each of the three domains of factor B (Ba, vWF and SP) demonstrated that each domain independently inhibited the binding of intact factor B to C3b by ∼50%.
Related Results
Activation of the Alternative Complement Pathway by Escherichia Coli: Resistance of Bound C3b to Inactivation by C3bINA and β1H
Activation of the Alternative Complement Pathway by Escherichia Coli: Resistance of Bound C3b to Inactivation by C3bINA and β1H
Abstract
The surfaces of activators of the alternative pathway, such as zymosan and rabbit erythrocytes, provide sites which protect bound C3b from inactivation by C...
Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
Introduction: the alternative pathway (AP) of complement activation plays a significant role in the pathophysiology of sickle cell disease (SCD), contributing to hemolysis and subs...
Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes.
Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes.
Abstract
We isolated the IgM fraction from the plasma of an SLE patient with high titer anti-dsDNA antibodies and prepared soluble IgM/dsDNA immune complexes (IC)...
Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
Introduction: complement activation plays a crucial role in the immune response and has been increasingly recognized for its involvement in various hemolytic anemias. In sickle cel...
KEDUDUKAN AHLI BAHASA DALAM PEMBUKTIAN PERKARA PENCEMARAN NAMA BAIK (STUDI PUTUSAN NOMOR: 47/PID.SUS/2019/PN. MGT)
KEDUDUKAN AHLI BAHASA DALAM PEMBUKTIAN PERKARA PENCEMARAN NAMA BAIK (STUDI PUTUSAN NOMOR: 47/PID.SUS/2019/PN. MGT)
<em><span id="page3R_mcid52" class="markedContent"><span style="left: calc(var(--scale-factor)*125.30px); top: calc(var(--scale-factor)*539.11px); font-size: calc(va...
Modulation of Macrophage C3b Receptor Function by Cytochalasin-Sensitive Structures
Modulation of Macrophage C3b Receptor Function by Cytochalasin-Sensitive Structures
Abstract
A quantitative rosette assay was employed in order to determine if through pharmacologic probes we could gain an insight into the nature of the interaction ...
Nanobodies targeting complement
Nanobodies targeting complement
The complement system is an important part of the human immune system that fights invading pathogens and removes apoptotic host cells, tumor cells and immune complexes. It consists...
The Physiological Breakdown of C3b
The Physiological Breakdown of C3b
Abstract
The requirements for and products of C3b inactivator (KAF) action on C3b have been studied. C3 was purified from human serum. Final traces of contaminating ...

